- Home
- TMQ vs CLSD Comparison
TMQ vs CLSD Comparison
Compare TMQ & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- CLSD
- Stock Information
- Founded
- TMQ 2004
- CLSD 2011
- Country
- TMQ Canada
- CLSD United States
- Employees
- TMQ N/A
- CLSD N/A
- Industry
- TMQ Precious Metals
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- TMQ Basic Materials
- CLSD Health Care
- Exchange
- TMQ Nasdaq
- CLSD Nasdaq
- Market Cap
- TMQ 83.6M
- CLSD 76.6M
- IPO Year
- TMQ N/A
- CLSD 2016
- Fundamental
- Price
- TMQ $1.10
- CLSD $1.00
- Analyst Decision
- TMQ
- CLSD Strong Buy
- Analyst Count
- TMQ 0
- CLSD 6
- Target Price
- TMQ N/A
- CLSD $5.33
- AVG Volume (30 Days)
- TMQ 439.1K
- CLSD 230.0K
- Earning Date
- TMQ 02-07-2025
- CLSD 11-12-2024
- Dividend Yield
- TMQ N/A
- CLSD N/A
- EPS Growth
- TMQ N/A
- CLSD N/A
- EPS
- TMQ N/A
- CLSD N/A
- Revenue
- TMQ N/A
- CLSD $7,703,000.00
- Revenue This Year
- TMQ N/A
- CLSD N/A
- Revenue Next Year
- TMQ N/A
- CLSD $91.87
- P/E Ratio
- TMQ N/A
- CLSD N/A
- Revenue Growth
- TMQ N/A
- CLSD 248.39
- 52 Week Low
- TMQ $0.25
- CLSD $0.92
- 52 Week High
- TMQ $1.40
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- TMQ 51.44
- CLSD 42.14
- Support Level
- TMQ $1.08
- CLSD $0.99
- Resistance Level
- TMQ $1.20
- CLSD $1.05
- Average True Range (ATR)
- TMQ 0.08
- CLSD 0.05
- MACD
- TMQ -0.02
- CLSD 0.00
- Stochastic Oscillator
- TMQ 38.46
- CLSD 15.38
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-lead-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.